header logo image

Lexington biotech plots $86M IPO as key gene therapy trial nears – Boston Business Journal

September 3rd, 2017 7:48 pm

Boston Business Journal
Lexington biotech plots $86M IPO as key gene therapy trial nears
Boston Business Journal
A Lexington biotech developing gene therapy treatments for rare eye diseases has announced plans to raise up to $86 million in an initial public offering. Nightstar Therapeutics, a 23-employee company with a 3,300 square foot office in Lexington and a ...
Nightstar files for $86M IPO to fund gene therapy trialsFierceBiotech

all 14 news articles »

Original post:
Lexington biotech plots $86M IPO as key gene therapy trial nears - Boston Business Journal

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick